Results 1 to 10 of about 2,974 (211)

Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection [PDF]

Pharmaceutics
Background/Objectives: Vascular graft infections (VGIs) represent a life-threatening complication, occurring in 0.2–6% of patients following aortic prosthetic placements. Historically, the primary focus for reducing VGIs has been on prevention. Currently,
Inês Cruz, Stefano Di Bella, Mario D’Oria, Cristina Lagatolla, M. Cristina L. Martins, Cláudia Monteiro   +5 more
doaj   +5 more sources

Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM) [PDF]

IDCases
Oritavancin is a novel long-acting lipoglycopeptide with in vitro activity against methicillin-resistant (MR) Gram-positive pathogens and a good bactericidal activity even in presence of biofilm forming bacteria.
A.R. Buonomo, L. Cattaneo, G. Viceconte, F. Calabria, G. Di Troia, A. Di Fusco, J. Mula, A. Cozzolino, L. Ametrano, A. D’Avolio, I. Gentile   +10 more
doaj   +5 more sources

Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use [PDF]

Drugs in Context
Background: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis ...
Alex Soriano, Carlo Tascini, Marco Falcone, Laura Morata, Marco Bongiovanni, Federico Pea, Pierluigi Viale   +6 more
doaj   +2 more sources

Oritavancin as sequential therapy for Gram-positive bloodstream infections

BMC Infectious Diseases, 2023
Background Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms.
Williams Monier Texidor, Matthew A. Miller, Kyle C. Molina, Martin Krsak, Barbara Calvert, Caitlin Hart, Marie Storer, Douglas N. Fish   +7 more
doaj   +3 more sources

Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes [PDF]

BMC Infectious Diseases
Background LVAD utility in heart failure patients is growing. Despite advancement in technology rates of LVAD- related infections remain high limiting outcomes. We aimed to assess the effectiveness and safety of oritavancin for LVAD-related Gram-positive
Marta Załęska-Kocięcka, Szymon Mielczarek, Piotr Góral, Kamil Marcinkiewicz, Katarzyna Byczkowska, Karina Zatorska, Justyna Cieślik, Karolina Paszyń, Aleksandra Tomaszek, Piotr Kołsut, Katarzyna Jóźwik-Plebanek, Jarosław Kuriata, Jarosław Szymański, Przemysław Leszek   +13 more
doaj   +2 more sources

Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review [PDF]

Antibiotics
Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. While their efficacy has been described in osteomyelitis, bacteremia, and infective endocarditis, evidence ...
Francesca Gavaruzzi, Guido Granata, Alessandro Capone, Pierangelo Chinello, Stefania Cicalini   +4 more
doaj   +2 more sources

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis [PDF]

Drugs - Real World Outcomes, 2020
Background Antibiotics for the treatment of complicated, multidrug-resistant Gram-positive infections are limited, especially when prolonged treatment is necessary.
Warren E. Rose, Paul R. Hutson
doaj   +3 more sources

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis [PDF]

Case Reports in Dermatology
Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases
Jina Bai, Emily Frech Preciado, Mary Baxter Harlow, Nina Blank   +3 more
doaj   +2 more sources

Oritavancin: A Long-Half-Life Lipoglycopeptide [PDF]

Clinical Infectious Diseases, 2015
Oritavancin is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). This antibiotic has multiple mechanisms of action including inhibiting peptidoglycan cell wall synthesis and disrupting bacterial cell membrane, leading to cell death.
Louis D, Saravolatz, Gary E, Stein
exaly   +3 more sources

Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature [PDF]

Antibiotics
Background: Bone and joint infections (BJIs), including osteomyelitis, septic arthritis, and periprosthetic joint infections, typically require prolonged antimicrobial therapy and often involve complex outpatient management.
Zain Ahmed Raza, Alex Giannini, Marco Bongiovanni   +2 more
doaj   +2 more sources